Overview
To validate the use of ICG as a tracer during TAD in patients with cN1 breast carcinoma after neoadjuvant chemotherapy.
Eligibility
Inclusion Criteria:
- Breast cancer cN+ patients who undergo neadjuvant treatment.
Exclusion Criteria:
- Patients in whom there is a contraindication for the use of ICG.
- Patients in whom there is evidence of progression of the disease after neoadjuvant treatment.